Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (ERAS) is a clinical-stage precision oncology company pioneering therapies for cancers driven by RAS/MAPK pathway abnormalities. This page serves as the definitive source for official updates spanning clinical developments, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated news about Erasca’s pipeline candidates including pan-RAF inhibitor naporafenib, ERK1/2 inhibitor ERAS-007, and emerging preclinical assets. Our repository includes trial progress reports, partnership announcements, and scientific presentations – all essential for tracking advancements in targeted cancer therapies.
Regular updates cover key areas: clinical trial phase transitions, FDA designations, collaborative research agreements, and preclinical discoveries. Each release is vetted for accuracy, providing reliable insights into Erasca’s mission to disrupt oncogenic signaling pathways.
Bookmark this page for streamlined access to ERAS news. Combine our updates with SEC filings and scientific publications for comprehensive analysis of this innovative oncology biotech.
Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, has announced its participation in two major investor conferences in June 2025:
1. Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 4 at 5:30 PM ET
2. Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11) in Miami Beach, with a fireside chat scheduled for June 10 at 2:40 PM ET
Management will participate in one-on-one investor meetings at both conferences. Live audio webcasts will be available at Erasca.com/events, with replays accessible for 30 days after each event.
Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.
Erasca presented new preclinical data at the 2025 AACR Annual Meeting, highlighting advances in their RAS-targeting cancer therapy franchise. The company showcased two key compounds:
ERAS-0015, a pan-RAS molecular glue, demonstrated:
- 8-21 times greater cyclophilin A binding versus competitor RMC-6236
- Strong anti-tumor activity at lower doses
- Effective tumor tissue distribution
ERAS-4001, a novel pan-KRAS inhibitor, showed:
- Selective targeting of both mutant and wildtype KRAS
- Strong tumor growth inhibition in multiple models
- Promising results when combined with anti-PD-1 or cetuximab
Additionally, the company identified first-in-class direct SHOC2 binders, representing a new approach to block cancer-causing RAS/MAPK pathway signaling. These developments reinforce Erasca's position in precision oncology for RAS/MAPK pathway-driven cancers.
Erasca (NASDAQ: ERAS) has announced three poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations will showcase the company's advancements in precision oncology, specifically targeting RAS/MAPK pathway-driven cancers.
The presentations will feature:
- ERAS-0015: A potential best-in-class pan-RAS molecular glue, to be presented on April 27
- ERAS-4001: A pan-KRAS inhibitor showing robust anti-tumor activity, scheduled for April 29
- Novel direct SMP complex inhibitors, representing a potential first-in-class approach to block the RAS/MAPK pathway, to be presented on April 28
All posters will be available on Erasca's website following the presentations.
Erasca (NASDAQ: ERAS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its RAS-targeting oncology programs. The company maintains a strong financial position with $440.5 million in cash and equivalents, expected to fund operations into H2 2027.
Key developments include the advancement of two promising candidates: ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), both scheduled to enter clinical trials in 2025. The ongoing Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma is progressing well, with Stage 1 randomized data expected in H2 2025.
Financial results show R&D expenses of $26.1 million for Q4 2024 and $115.4 million for the full year. The company reported a net loss of $32.2 million for Q4 and $161.7 million for the full year 2024, or $(0.69) per share.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The event will take place at the Lotte New York Palace in New York.
The company's management will conduct a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will engage in one-on-one investor meetings. Interested parties can access a live audio webcast of the presentation through Erasca.com/events, where an archived replay will remain available for 30 days following the event.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.
The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.
Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
